Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?
- 1k Downloads
The recent JUPITER trial demonstrated that potent statin therapy reduces by 50 % the risk of heart attack and stroke among men and women with low levels of low-density lipoprotein (LDL)-cholesterol who are at increased vascular risk due to elevated levels of C-reactive protein (CRP), a biomarker of low-grade systemic inflammation. In JUPITER, both absolute risk and the absolute risk reduction with statin therapy were related to the level of CRP, whereas no such relationship was observed for LDL-C. Further, on-treatment levels of CRP and LDL-C were independently associated with residual risk, and the genetic determinants of statin-induced CRP reduction differed from the genetic determinants of statin-induced LDL reduction. Despite these data, it is impossible in any statin trial to establish whether the clinical benefits of treatment are due to LDL-reduction alone, to inflammation inhibition, or to a combination of both processes. To address the hypothesis that lowering inflammation will lower vascular event rates, two large-scale placebo controlled trials using targeted anti-inflammatory agents for the secondary prevention of myocardial infarction have been initiated. The first trial, the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), is evaluating whether interleukin-1β (IL-1β) inhibition as compared to placebo can reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients who remain at high vascular risk due to persistent elevations of hsCRP (≥ 2 mg/L), despite contemporary secondary prevention strategies. The second trial, the Cardiovascular Inflammation Reduction Trial (CIRT) has been funded by the National Heart, Lung, and Blood Institute (NHLBI) and will evaluate whether low dose methotrexate (target dose 20 mg/week) as compared to placebo will reduce major vascular events among a group of post-myocardial infarction patients with either diabetes or metabolic syndrome, groups known to have high risk on the basis of a persistent pro-inflammatory response. Together, CANTOS and CIRT represent a core test of the inflammation hypothesis of atherothrombosis and the exploration of a potential new phase for cardiovascular therapeutics.
KeywordsInflammation Clinical trials C-reactive protein Interleukin-1 Atherosclerosis Diabetes Statin therapy
P.M. Ridker: Listed as a co-inventor on patents held by the Brigham and Women’s Hospital (BWH) that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to Siemens and AstraZeneca. Dr. Ridker is the Principle Investigator of the Cardiovascular Inflammation Reduction Trial (CIRT) (funded by the National Heart Lung and Blood Institute) and the Principle Investigator of the Canakinumab Anti-inflammaatory Throbosis Outcomes Study (CANTOS) (funded by Novartis). Neither Dr. Ridker nor the BWH will receive any royalties related to the use of the CRP test in either of these trials.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.•• Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40. This meta-analysis of over 54 prospective cohort studies demonstrated that the magnitude of impact inflammation has on future vascular events is at least as large as that of cholesterol or blood pressure, even after adjustment for traditional risk markers. PubMedCrossRefGoogle Scholar
- 6.• Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, et al. Comparison of the Framingham and Reynolds Risk Scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation. 2012;125:1748–56. This direct comparison indicates that the Reynolds Risk Score outperforms the more traditional Framingham Risk Score, an important paper since Reynolds includes both CRP and family history. PubMedCrossRefGoogle Scholar
- 7.Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–44.PubMedCrossRefGoogle Scholar
- 11.McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009;120:2188–96.PubMedCrossRefGoogle Scholar
- 13.•• Braunwald E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J. 2012;33:430–2. An excellent overview describing common misunderstadings and controversies with regard to the inflammation hypothesis of atherosclerosis. PubMedCrossRefGoogle Scholar
- 15.Mora S, Glynn RJ, Hsia J, Macfadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Results from the Justification for the Use of Statins in Prevention: An intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–77.PubMedCrossRefGoogle Scholar
- 16.Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488–96.PubMedGoogle Scholar
- 17.Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009;2:616–23.PubMedCrossRefGoogle Scholar
- 20.• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82. This paper from the JUPITER trial demonstrates that lowering CRP was as important as lowering LDL-C in terms of preventing first ever vascular events. PubMedCrossRefGoogle Scholar
- 21.Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010;106:204–9.PubMedCrossRefGoogle Scholar
- 23.Chasman DI, Guilianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statini-induced low-density lipoprotein cholesterol reduction. The Justificaton for the Use of statins in Prevention: an Intervention Trial Evalauting Rosuvastatin (JUPITER) Trial. Circ Cardiovasc Genet. 2012;5:257–64.PubMedCrossRefGoogle Scholar
- 25.• Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597–605. This is the formal rationale and design paper for the CANTOS trial and contains full details of the protocol. PubMedCrossRefGoogle Scholar
- 26.•• Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61. An important biologic paper describing the role played by cholesterol crystals in activating the inflammasome and thus leading to increased interleukin-1 production. PubMedCrossRefGoogle Scholar
- 35.• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362–70. A meta-analysis of non-randomized data indicating the reduced rate of vascular events in arthritis patients being treated with low dose methotrexate. PubMedCrossRefGoogle Scholar
- 39.Coomes E, Chan ES, Reiss AB. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol 2011;503028.Google Scholar